SALT LAKE CITY--(BUSINESS WIRE)--CirTran Beverage Corp., a subsidiary of CirTran Corporation (OTC BB:CIRC) and Play Beverages, LLC said today that they have filed an appeal of the adverse jury verdict and related orders entered in favor of Playboy Enterprises in the long-running trademark and licensing dispute between the parties concerning Playboy Energy Drink.
The appeal, filed on July 21, 2017, asks that all relief awarded to Playboy be vacated and that a new trial be granted to CirTran Beverage and Play Beverages on each of their claims.
CirTran Beverage and Play Beverages brought the lawsuit against Playboy in 2012 seeking to enforce contractual and related rights to manufacture and market a line of energy drinks using the Playboy trademarks.
Iehab J. Hawatmeh, president of CirTran Beverage, said that veteran trial lawyer Todd C. Jacobs from litigation boutique Bradley Riley Jacobs PC of Chicago has been retained in the appeal.
“CirTran Beverage and Play Beverages were extremely disappointed by the outcome in the trial court,” Mr. Hawatmeh said. “However, we believe in the justice system and that our rights will ultimately be vindicated on appeal and at a retrial of this matter.”
About CirTran Corporation
Founded in 1993, CirTran Corporation has evolved from its roots in electronics to also manufacture and market beverages through its CirTran Beverage subsidiary. CirTran also maintains the capabilities of its previous core business in off-shore manufacturing of high-volume electronics, fitness equipment and household products.
This press release contains forward-looking statements within the meaning of section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. With the exception of historical information contained herein, the matters discussed in this press release involve risk and uncertainties. Actual results could differ materially from those expressed in any forward-looking statement. CirTran disclaims any obligation or intention to update any forward-looking statement.